Find Locations
For hours, walk-ins and appointments.Unable to load global navigation.
Synonyms
- Androstaner-3-one
- DHT
- Hydroxy-5α
Expected Turnaround Time
5 - 10 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Related Documents
Specimen Requirements
Specimen
Serum (preferred) or plasma, frozen
Volume
1 mL
Minimum Volume
0.5 mL (Note: This volume does not allow for repeat testing.)
Container
Red-top tube, gel-barrier tube, lavender-top (EDTA) tube, or green-top (heparin) tube
Collection
Separate serum or plasma from cells within one hour of collection. Send serum or plasma in plastic transport tube. Transfer specimen to a plastic transport tube before freezing. To avoid delays in turnaround time when requesting multiple tests on frozen samples, please submit separate frozen specimens for each test requested.
Storage Instructions
Freeze
Stability Requirements
Temperature | Period |
|---|---|
Room temperature | 7 days |
Refrigerated | 7 days |
Frozen | 19 months |
Freeze/thaw cycles | Stable x6 |
Test Details
Use
Dihydrotestosterone and dihydrotestosterone/ratio may be used for differential diagnosis of diseases of sexual differentiation (DSD). DHT levels may be inappropriately low compared to testosterone levels in 5a-reductase deficiency. It is recommended by guidelines to measure the ratio of testosterone to DHT.
DHT levels may also be monitored to follow the effectiveness of 5a-reductase inhibitor treatment in female alopecia.
Limitations
This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.
Methodology
High-pressure liquid chromatography (HPLC) with tandem mass spectrometry
References
Douglas G, Axelrad ME, Brandt ML, et.al. Guidelines for Evaluating and Managing Children Born with Disorders of Sexual Development. Pediatr Ann. 2012 Apr:41(4):e1-e7.22494213
Goodman NF, Cobin RH, Futterweit W, et. al. Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome--Part 1. Endocr Pract. 2015 Nov;21(11):1291-1300.26509855
Hughes IA, Houk C, Ahmed SF, Lee PA; LWPES Consensus Group; ESPE Consensus Group. Consensus statement on management of intersex disorders. Arch Dis Child. 2006 Jul;91(7):554-563.16624884
Ocal G. Current Concepts in Disorders of Sexual Development. J Clin Res Pediatr Endocrinol. 2011;3(3):105-114.21911322
LOINC® Map
| Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
|---|---|---|---|---|---|---|
| 500142 | Dihydrotestosterone | 1848-1 | 500143 | Dihydrotestosterone | ng/dL | 1848-1 |
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf